> During 1,915,120 person-years of observation, 218 persons developed NAION. Semaglutide 51 exposure associated with a higher incidence rate (0·228 vs 0·093 per 1000 person-years, p<0·001) 52 and independently predicted a higher risk of upcoming NAION (HR 2·19, 95% confidence interval 53 1·54-3·12), even when multiple other factors were taken into account.
> In this cohort study conducted in Denmark and Norway, use of semaglutide was associated with an increased risk of NAION; the pooled hazard ratio was 2.81 (95% confidence interval (CI) 1.67 to 4.75) and the incidence rate difference (absolute risk increase) was +1.41 (95% CI +0.53 to +2.29) NAION events per 10,000 person-years. The finding was consistent across sensitivity and supplementary analysis.